Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells

	Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
	Hou, Zhi-Jie 1,2; Luo, Xi 1,2; Zhang, Wei 1,2; Peng, Fei 1,2; Cui, Bai 1,2; Wu, Si-Jin 3; Zheng, Fei-Meng 1,2; Xu, Jie 1,2; Xu, Ling-Zhi 1,2; Long, Zi-Jie 4
刊名	oncotarget
	2015-03-20
卷号	6 期号:8 页码:6326-6340
关键词	flubendazole breast cancer cancer stem-like cell cell cycle tubulin
英文摘要	cancer stem-like cell (cs-like cell) is considered to be responsible for recurrence and drug resistance events in breast cancer, which makes it a potential target for novel cancer therapeutic strategy. the fda approved flubendazole, has been widely used in the treatment of intestinal parasites. here, we demonstrated a novel effect of flubendazole on breast cs-like cells. flubendazole inhibited breast cancer cells proliferation in dose-and time-dependent manner and delayed tumor growth in xenograft models by intraperitoneal injection. importantly, flubendazole reduced cd44(high)/cd24(low) subpopulation and suppressed the formation of mammosphere and the expression of self-renewal related genes including c-myc, oct4, sox2, nanog and cyclind1. moreover, we found that flubendazole induced cell differentiation and inhibited cell migration. consistently, flubendazole reduced mesenchymal markers (beta-catenin, n-cadherin and vimentin) expression and induced epithelial and differentiation marker (keratin 18) expression in breast cancer cells. mechanism study revealed that flubendazole arrested cell cycle at g2/m phase and induced monopolar spindle formation through inhibiting tubulin polymerization. furthermore, flubendazole enhanced cytotoxic activity of conventional therapeutic drugs fluorouracil and doxorubicin against breast cancer cells. in conclusion, our findings uncovered a remarkable effect of flubendazole on suppressing breast cs-like cells, indicating a novel utilization of flubendazole in breast cancer therapy.
WOS标题词	science & technology ; life sciences & biomedicine
类目[WOS]	oncology ; cell biology
研究领域[WOS]	oncology ; cell biology
关键词[WOS]	epithelial-mesenchymal transition ; neoadjuvant chemotherapy ; diabetic-patients ; initiating cells ; drug-resistance ; side population ; tumor-cells ; albendazole ; expression ; therapy
收录类别	SCI
语种	英语
WOS记录号	WOS:000352793000061
公开日期	2016-05-09
内容类型	期刊论文
源URL	[http://cas-ir.dicp.ac.cn/handle/321008/146190]
专题	大连化学物理研究所_中国科学院大连化学物理研究所
作者单位	1.Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China 2.Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China 3.Dalian Univ Technol, Ctr Mol Med, Sch Life Sci & Biotechnol, Dalian, Peoples R China 4.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hematol, Guangzhou 510275, Guangdong, Peoples R China 5.Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Mol React Dynam, Lab Mol Modeling & Design, Dalian, Peoples R China 6.Dalian Med Univ, Dept Crit Care Med, Affiliated Hosp 1, Dalian, Peoples R China
推荐引用方式 GB/T 7714	Hou, Zhi-Jie,Luo, Xi,Zhang, Wei,et al. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells[J]. oncotarget,2015,6(8):6326-6340.
APA	Hou, Zhi-Jie.,Luo, Xi.,Zhang, Wei.,Peng, Fei.,Cui, Bai.,...&Liu, Quentin.(2015).Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.oncotarget,6(8),6326-6340.
MLA	Hou, Zhi-Jie,et al."Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells".oncotarget 6.8(2015):6326-6340.